AG˹ٷ

STOCK TITAN

[S-8] Lexicon Pharmaceuticals, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

Investar Holding Corp. (ISTR) Q2 2025 10-Q highlights

Net income rose 11% YoY to $4.5 million, lifting basic EPS to $0.46 from $0.41. Higher net interest income (+14% YoY to $19.6 million) outweighed a modest $0.1 million credit-loss provision (vs. a $0.4 million release last year). Total interest expense fell 15% to $15.7 million, reflecting lower borrowing costs, while interest income was stable at $35.4 million.

Balance sheet: Assets expanded to $2.75 billion (+1% vs. 12/24). Loans declined 0.9% to $2.11 billion, but deposits were essentially flat at $2.34 billion (non-interest deposits +3.8%; interest-bearing �1.3%). The allowance for credit losses remained steady at $26.6 million (1.26% of loans). Tangible equity improved to $255.9 million as unrealized AFS losses narrowed to $-41.6 million from $-48.4 million, aided by a $6.7 million OCI gain YTD.

Operating trends: Non-interest income slipped 4% to $2.6 million, while non-interest expense climbed 8% to $16.7 million on higher compensation and acquisition costs. The efficiency ratio improved modestly as revenue growth outpaced expenses. Year-to-date, a $3.5 million negative provision boosted net income to $10.8 million (+23%).

Capital & dividends: 9.84 million shares outstanding; cash dividend raised to $0.11/sh (vs. $0.10). The company repurchased 71 k shares YTD and received $17.3 million of proceeds from a pending Series A preferred offering.

Key risk metrics remain stable; no material credit deterioration disclosed. Management continues to focus on spread expansion, balance-sheet remix toward non-interest deposits, and capital return.

Investar Holding Corp. (ISTR) Q2 2025 evidenze del 10-Q

L'utile netto è aumentato dell'11% su base annua raggiungendo 4,5 milioni di dollari, portando l'EPS base a 0,46$ da 0,41$. L'incremento del reddito netto da interessi (+14% YoY a 19,6 milioni di dollari) ha compensato una modesta accantonamento per perdite su crediti di 0,1 milioni di dollari (rispetto a un rilascio di 0,4 milioni l'anno scorso). La spesa totale per interessi è diminuita del 15% a 15,7 milioni di dollari, riflettendo costi di indebitamento più bassi, mentre il reddito da interessi è rimasto stabile a 35,4 milioni di dollari.

Bilancio: Gli attivi sono cresciuti a 2,75 miliardi di dollari (+1% rispetto a dicembre 2024). I prestiti sono diminuiti dello 0,9% a 2,11 miliardi, ma i depositi sono rimasti sostanzialmente invariati a 2,34 miliardi (depositi senza interessi +3,8%; depositi a interesse -1,3%). L'accantonamento per perdite su crediti è rimasto stabile a 26,6 milioni di dollari (1,26% dei prestiti). Il patrimonio tangibile è migliorato a 255,9 milioni di dollari grazie alla riduzione delle perdite non realizzate su titoli disponibili per la vendita a -41,6 milioni da -48,4 milioni, supportata da un guadagno OCI di 6,7 milioni da inizio anno.

Tendenze operative: Il reddito non da interessi è sceso del 4% a 2,6 milioni di dollari, mentre le spese non da interessi sono aumentate dell'8% a 16,7 milioni a causa di maggiori costi per compensi e acquisizioni. Il rapporto di efficienza è migliorato leggermente poiché la crescita dei ricavi ha superato le spese. Da inizio anno, una svalutazione negativa di 3,5 milioni ha portato l'utile netto a 10,8 milioni (+23%).

Capitale e dividendi: 9,84 milioni di azioni in circolazione; dividendo in contanti aumentato a 0,11$ per azione (da 0,10$). La società ha riacquistato 71 mila azioni da inizio anno e ha incassato 17,3 milioni di dollari da una prossima offerta di azioni privilegiate di Serie A.

I principali indicatori di rischio restano stabili; non sono state segnalate deterioramenti significativi del credito. Il management continua a concentrarsi sull’espansione dello spread, sulla ristrutturazione del bilancio verso depositi senza interessi e sul ritorno del capitale agli azionisti.

Aspectos destacados del 10-Q del 2T 2025 de Investar Holding Corp. (ISTR)

El ingreso neto aumentó un 11% interanual hasta 4,5 millones de dólares, elevando el EPS básico a 0,46$ desde 0,41$. El mayor ingreso neto por intereses (+14% interanual a 19,6 millones) compensó una modesta provisión por pérdidas crediticias de 0,1 millones (frente a una reversión de 0,4 millones el año pasado). El gasto total por intereses cayó un 15% a 15,7 millones, reflejando menores costos de financiamiento, mientras que el ingreso por intereses se mantuvo estable en 35,4 millones.

Balance: Los activos crecieron a 2,75 mil millones (+1% respecto a diciembre de 2024). Los préstamos disminuyeron un 0,9% a 2,11 mil millones, pero los depósitos se mantuvieron prácticamente estables en 2,34 mil millones (depósitos sin intereses +3,8%; depósitos con intereses -1,3%). La provisión para pérdidas crediticias se mantuvo estable en 26,6 millones (1,26% de los préstamos). El capital tangible mejoró a 255,9 millones ya que las pérdidas no realizadas en valores disponibles para la venta se redujeron a -41,6 millones desde -48,4 millones, apoyado por una ganancia OCI de 6,7 millones en el año hasta la fecha.

Tendencias operativas: Los ingresos no por intereses bajaron un 4% a 2,6 millones, mientras que los gastos no por intereses aumentaron un 8% a 16,7 millones debido a mayores costos de compensación y adquisiciones. La ratio de eficiencia mejoró ligeramente ya que el crecimiento de ingresos superó los gastos. En lo que va del año, una provisión negativa de 3,5 millones impulsó el ingreso neto a 10,8 millones (+23%).

Capital y dividendos: 9,84 millones de acciones en circulación; dividendo en efectivo aumentado a 0,11$ por acción (desde 0,10$). La compañía recompró 71 mil acciones en lo que va del año y recibió 17,3 millones de dólares por una oferta pendiente de acciones preferentes Serie A.

Las métricas clave de riesgo permanecen estables; no se reportaron deterioros crediticios materiales. La dirección sigue enfocada en la expansión del margen, la reestructuración del balance hacia depósitos sin intereses y el retorno de capital.

Investar Holding Corp. (ISTR) 2025� 2분기 10-Q 주요 내용

순이익은 전년 대� 11% 증가� 450� 달러�, 기본 주당순이�(EPS)은 0.41달러에서 0.46달러� 상승했습니다. 숵ӝ자수�은 전년 대� 14% 증가� 1,960� 달러�, 10� 달러� 대손충당금 설정(작년에는 40� 달러 환입)� 상쇄했습니다. � 이자 비용은 차입 비용 감소� 15% 감소� 1,570� 달러였으며, 이자 수익은 3,540� 달러� 안정적이었습니다.

댶차대조표: 자산은 27� 5천만 달러� 1% 증가(2024� 12� 대�)했습니다. 대출금은 0.9% 감소� 21� 1천만 달러였으나, 예금은 거의 변� 없이 23� 4천만 달러(비이� 예금 +3.8%; 이자부 예금 -1.3%)였습니�. 대손충당금은 2,660� 달러� 대출금� 1.26% 수준에서 안정적이었습니다. 유형자본은 미실� 매도가능증� 손실� 4,160� 달러에서 4,840� 달러� 축소되고, 연초 이후 670� 달러� 기타포괄손익(OCI) 이익� 반영되어 2� 5,590� 달러� 개선되었습니�.

운영 동향: 비이� 수익은 4% 감소� 260� 달러였�, 비이� 비용은 보상 � 인수 비용 증가� 8% 상승� 1,670� 달러였습니�. 수익 증가가 비용 증가� 앞서� 효율� 비율은 소폭 개선되었습니�. 연초부터는 350� 달러� 부정적 충당� 설정으로 순이익이 1,080� 달러(+23%)� 증가했습니다.

자본 � 배당: 발행 주식 수는 984� 주이�, 현금 배당금은 주당 0.11달러� 인상(이전 0.10달러)되었습니�. 회사� 연초 이후 7� 1� 주를 재매입했�, 예정� 시리� A 우선� 발행으로 1,730� 달러� 자금� 확보했습니다.

주요 위험 지표는 안정적이�, 신용 악화� 보고되지 않았습니�. 경영진은 스프레드 확대, 비이� 예금 중심으로 댶차대조표 구조 조정, 자본 환원� 계속 집중하고 있습니다.

Points clés du 10-Q du 2e trimestre 2025 d'Investar Holding Corp. (ISTR)

Le bénéfice net a augmenté de 11 % en glissement annuel pour atteindre 4,5 millions de dollars, portant le BPA de base à 0,46 $ contre 0,41 $. Les revenus nets d'intérêts plus élevés (+14 % en glissement annuel à 19,6 millions de dollars) ont compensé une provision pour pertes sur crédits modeste de 0,1 million de dollars (contre une reprise de 0,4 million l'an dernier). Les charges d'intérêts totales ont diminué de 15 % à 15,7 millions, reflétant des coûts d'emprunt plus faibles, tandis que les produits d'intérêts sont restés stables à 35,4 millions.

Bilan : Les actifs ont augmenté à 2,75 milliards (+1 % par rapport à décembre 2024). Les prêts ont diminué de 0,9 % à 2,11 milliards, mais les dépôts sont restés pratiquement stables à 2,34 milliards (dépôts sans intérêts +3,8 % ; dépôts à intérêt -1,3 %). La provision pour pertes sur crédits est restée stable à 26,6 millions (1,26 % des prêts). Les capitaux propres tangibles se sont améliorés à 255,9 millions grâce à une réduction des pertes non réalisées sur titres disponibles à la vente à -41,6 millions contre -48,4 millions, soutenue par un gain OCI de 6,7 millions depuis le début de l'année.

Tendances opérationnelles : Les revenus hors intérêts ont diminué de 4 % à 2,6 millions, tandis que les charges hors intérêts ont augmenté de 8 % à 16,7 millions en raison de coûts plus élevés en matière de rémunérations et d'acquisitions. Le ratio d'efficacité s'est légèrement amélioré car la croissance des revenus a dépassé les dépenses. Depuis le début de l'année, une provision négative de 3,5 millions a porté le bénéfice net à 10,8 millions (+23 %).

Capital et dividendes : 9,84 millions d'actions en circulation ; dividende en espèces augmenté à 0,11 $ par action (contre 0,10 $). La société a racheté 71 000 actions depuis le début de l'année et a reçu 17,3 millions de dollars de produits d'une émission en attente d'actions préférentielles de série A.

Les principaux indicateurs de risque restent stables ; aucune dégradation significative du crédit n’a été signalée. La direction continue de se concentrer sur l’élargissement des marges, la réorganisation du bilan vers des dépôts non rémunérés et le retour de capital.

Investar Holding Corp. (ISTR) Q2 2025 10-Q Highlights

Der Nettogewinn stieg im Jahresvergleich um 11 % auf 4,5 Millionen US-Dollar, wodurch das Basis-Gewinn pro Aktie (EPS) von 0,41 $ auf 0,46 $ anstieg. Höhere ٳٴdzԲٰä (+14 % YoY auf 19,6 Millionen US-Dollar) übertrafen eine moderate Kreditverlustrückstellung von 0,1 Millionen US-Dollar (im Vergleich zu einer Auflösung von 0,4 Millionen im Vorjahr). Die gesamten Zinsaufwendungen sanken um 15 % auf 15,7 Millionen US-Dollar, was niedrigeren Kreditkosten entspricht, während die Zinserträge mit 35,4 Millionen stabil blieben.

Bilanz: Die Aktiva wuchsen auf 2,75 Milliarden US-Dollar (+1 % gegenüber Dezember 2024). Die Kredite sanken um 0,9 % auf 2,11 Milliarden, während die Einlagen mit 2,34 Milliarden im Wesentlichen stabil blieben (nicht verzinsliche Einlagen +3,8 %; verzinsliche Einlagen -1,3 %). Die Rückstellung für Kreditverluste blieb stabil bei 26,6 Millionen US-Dollar (1,26 % der Kredite). Das materielle Eigenkapital verbesserte sich auf 255,9 Millionen, da die unrealisierte AFS-Verluste von -48,4 Millionen auf -41,6 Millionen zurückgingen, unterstützt durch einen OCI-Gewinn von 6,7 Millionen im laufenden Jahr.

Operative Trends: Die Erträge ohne Zinsen sanken um 4 % auf 2,6 Millionen, während die Aufwendungen ohne Zinsen aufgrund höherer Vergütungs- und Akquisitionskosten um 8 % auf 16,7 Millionen stiegen. Die Effizienzquote verbesserte sich leicht, da das Umsatzwachstum die Kosten überstieg. Im Jahresverlauf führte eine negative Rückstellung von 3,5 Millionen zu einem Nettogewinn von 10,8 Millionen (+23 %).

Kapital & Dividenden: 9,84 Millionen ausstehende Aktien; Bardividende wurde auf 0,11 $ pro Aktie erhöht (vorher 0,10 $). Das Unternehmen hat im laufenden Jahr 71.000 Aktien zurückgekauft und 17,3 Millionen US-Dollar aus einem ausstehenden Series-A-Vorzugsaktien-Angebot erhalten.

Wesentliche Risikokennzahlen bleiben stabil; keine wesentliche Kreditverschlechterung gemeldet. Das Management konzentriert sich weiterhin auf die Ausweitung der Spreads, die Bilanzumstrukturierung zugunsten nicht verzinslicher Einlagen und die Kapitalrückführung.

Positive
  • EPS up 12% YoY to $0.46 on stronger NII and cost control.
  • Interest expense down 15%, signalling easing funding pressure.
  • Other comprehensive loss narrowed by $6.7 million, boosting tangible equity.
  • Provision release YTD of $3.5 million supports earnings and reflects stable credit.
Negative
  • Loan portfolio contracted 0.9% since year-end, indicating muted growth.
  • Non-interest expense rose 8%, led by salaries and acquisition costs.
  • $53 million unrealized AFS losses remain a capital and rate-risk overhang.

Insights

TL;DR: Solid EPS beat driven by lower funding costs; credit and capital stable.

ISTR’s Q2 print shows encouraging core performance: net interest income grew 14% despite flat asset levels because deposit repricing pressure has eased—interest expense dropped 15% YoY. Combined with negligible provisioning, this pushed ROA toward 0.66%. Equity rose 6% YTD as AOCI improved, enhancing tangible book value. Loan contraction and modest deposit runoff indicate tepid growth, but mix shifted to non-interest deposits, supporting margin durability. Overall, results are incrementally positive for valuation and dividend capacity.

TL;DR: Credit quality steady; unrealized losses still sizable but trending better.

The ACL ratio held at 1.26% of loans and management continued to release reserves YTD, signalling confidence in portfolio quality. Non-performing metrics were not flagged as rising. However, the securities book still carries $53 million of unrealized losses (13% of amortized cost), exposing capital to rate volatility, though the $8 million Q/Q improvement reduces pressure. Liquidity looks comfortable with $55 million cash and modest FHLB advances. No new regulatory or litigation concerns surfaced. Net risk trend is neutral-to-positive.

Investar Holding Corp. (ISTR) Q2 2025 evidenze del 10-Q

L'utile netto è aumentato dell'11% su base annua raggiungendo 4,5 milioni di dollari, portando l'EPS base a 0,46$ da 0,41$. L'incremento del reddito netto da interessi (+14% YoY a 19,6 milioni di dollari) ha compensato una modesta accantonamento per perdite su crediti di 0,1 milioni di dollari (rispetto a un rilascio di 0,4 milioni l'anno scorso). La spesa totale per interessi è diminuita del 15% a 15,7 milioni di dollari, riflettendo costi di indebitamento più bassi, mentre il reddito da interessi è rimasto stabile a 35,4 milioni di dollari.

Bilancio: Gli attivi sono cresciuti a 2,75 miliardi di dollari (+1% rispetto a dicembre 2024). I prestiti sono diminuiti dello 0,9% a 2,11 miliardi, ma i depositi sono rimasti sostanzialmente invariati a 2,34 miliardi (depositi senza interessi +3,8%; depositi a interesse -1,3%). L'accantonamento per perdite su crediti è rimasto stabile a 26,6 milioni di dollari (1,26% dei prestiti). Il patrimonio tangibile è migliorato a 255,9 milioni di dollari grazie alla riduzione delle perdite non realizzate su titoli disponibili per la vendita a -41,6 milioni da -48,4 milioni, supportata da un guadagno OCI di 6,7 milioni da inizio anno.

Tendenze operative: Il reddito non da interessi è sceso del 4% a 2,6 milioni di dollari, mentre le spese non da interessi sono aumentate dell'8% a 16,7 milioni a causa di maggiori costi per compensi e acquisizioni. Il rapporto di efficienza è migliorato leggermente poiché la crescita dei ricavi ha superato le spese. Da inizio anno, una svalutazione negativa di 3,5 milioni ha portato l'utile netto a 10,8 milioni (+23%).

Capitale e dividendi: 9,84 milioni di azioni in circolazione; dividendo in contanti aumentato a 0,11$ per azione (da 0,10$). La società ha riacquistato 71 mila azioni da inizio anno e ha incassato 17,3 milioni di dollari da una prossima offerta di azioni privilegiate di Serie A.

I principali indicatori di rischio restano stabili; non sono state segnalate deterioramenti significativi del credito. Il management continua a concentrarsi sull’espansione dello spread, sulla ristrutturazione del bilancio verso depositi senza interessi e sul ritorno del capitale agli azionisti.

Aspectos destacados del 10-Q del 2T 2025 de Investar Holding Corp. (ISTR)

El ingreso neto aumentó un 11% interanual hasta 4,5 millones de dólares, elevando el EPS básico a 0,46$ desde 0,41$. El mayor ingreso neto por intereses (+14% interanual a 19,6 millones) compensó una modesta provisión por pérdidas crediticias de 0,1 millones (frente a una reversión de 0,4 millones el año pasado). El gasto total por intereses cayó un 15% a 15,7 millones, reflejando menores costos de financiamiento, mientras que el ingreso por intereses se mantuvo estable en 35,4 millones.

Balance: Los activos crecieron a 2,75 mil millones (+1% respecto a diciembre de 2024). Los préstamos disminuyeron un 0,9% a 2,11 mil millones, pero los depósitos se mantuvieron prácticamente estables en 2,34 mil millones (depósitos sin intereses +3,8%; depósitos con intereses -1,3%). La provisión para pérdidas crediticias se mantuvo estable en 26,6 millones (1,26% de los préstamos). El capital tangible mejoró a 255,9 millones ya que las pérdidas no realizadas en valores disponibles para la venta se redujeron a -41,6 millones desde -48,4 millones, apoyado por una ganancia OCI de 6,7 millones en el año hasta la fecha.

Tendencias operativas: Los ingresos no por intereses bajaron un 4% a 2,6 millones, mientras que los gastos no por intereses aumentaron un 8% a 16,7 millones debido a mayores costos de compensación y adquisiciones. La ratio de eficiencia mejoró ligeramente ya que el crecimiento de ingresos superó los gastos. En lo que va del año, una provisión negativa de 3,5 millones impulsó el ingreso neto a 10,8 millones (+23%).

Capital y dividendos: 9,84 millones de acciones en circulación; dividendo en efectivo aumentado a 0,11$ por acción (desde 0,10$). La compañía recompró 71 mil acciones en lo que va del año y recibió 17,3 millones de dólares por una oferta pendiente de acciones preferentes Serie A.

Las métricas clave de riesgo permanecen estables; no se reportaron deterioros crediticios materiales. La dirección sigue enfocada en la expansión del margen, la reestructuración del balance hacia depósitos sin intereses y el retorno de capital.

Investar Holding Corp. (ISTR) 2025� 2분기 10-Q 주요 내용

순이익은 전년 대� 11% 증가� 450� 달러�, 기본 주당순이�(EPS)은 0.41달러에서 0.46달러� 상승했습니다. 숵ӝ자수�은 전년 대� 14% 증가� 1,960� 달러�, 10� 달러� 대손충당금 설정(작년에는 40� 달러 환입)� 상쇄했습니다. � 이자 비용은 차입 비용 감소� 15% 감소� 1,570� 달러였으며, 이자 수익은 3,540� 달러� 안정적이었습니다.

댶차대조표: 자산은 27� 5천만 달러� 1% 증가(2024� 12� 대�)했습니다. 대출금은 0.9% 감소� 21� 1천만 달러였으나, 예금은 거의 변� 없이 23� 4천만 달러(비이� 예금 +3.8%; 이자부 예금 -1.3%)였습니�. 대손충당금은 2,660� 달러� 대출금� 1.26% 수준에서 안정적이었습니다. 유형자본은 미실� 매도가능증� 손실� 4,160� 달러에서 4,840� 달러� 축소되고, 연초 이후 670� 달러� 기타포괄손익(OCI) 이익� 반영되어 2� 5,590� 달러� 개선되었습니�.

운영 동향: 비이� 수익은 4% 감소� 260� 달러였�, 비이� 비용은 보상 � 인수 비용 증가� 8% 상승� 1,670� 달러였습니�. 수익 증가가 비용 증가� 앞서� 효율� 비율은 소폭 개선되었습니�. 연초부터는 350� 달러� 부정적 충당� 설정으로 순이익이 1,080� 달러(+23%)� 증가했습니다.

자본 � 배당: 발행 주식 수는 984� 주이�, 현금 배당금은 주당 0.11달러� 인상(이전 0.10달러)되었습니�. 회사� 연초 이후 7� 1� 주를 재매입했�, 예정� 시리� A 우선� 발행으로 1,730� 달러� 자금� 확보했습니다.

주요 위험 지표는 안정적이�, 신용 악화� 보고되지 않았습니�. 경영진은 스프레드 확대, 비이� 예금 중심으로 댶차대조표 구조 조정, 자본 환원� 계속 집중하고 있습니다.

Points clés du 10-Q du 2e trimestre 2025 d'Investar Holding Corp. (ISTR)

Le bénéfice net a augmenté de 11 % en glissement annuel pour atteindre 4,5 millions de dollars, portant le BPA de base à 0,46 $ contre 0,41 $. Les revenus nets d'intérêts plus élevés (+14 % en glissement annuel à 19,6 millions de dollars) ont compensé une provision pour pertes sur crédits modeste de 0,1 million de dollars (contre une reprise de 0,4 million l'an dernier). Les charges d'intérêts totales ont diminué de 15 % à 15,7 millions, reflétant des coûts d'emprunt plus faibles, tandis que les produits d'intérêts sont restés stables à 35,4 millions.

Bilan : Les actifs ont augmenté à 2,75 milliards (+1 % par rapport à décembre 2024). Les prêts ont diminué de 0,9 % à 2,11 milliards, mais les dépôts sont restés pratiquement stables à 2,34 milliards (dépôts sans intérêts +3,8 % ; dépôts à intérêt -1,3 %). La provision pour pertes sur crédits est restée stable à 26,6 millions (1,26 % des prêts). Les capitaux propres tangibles se sont améliorés à 255,9 millions grâce à une réduction des pertes non réalisées sur titres disponibles à la vente à -41,6 millions contre -48,4 millions, soutenue par un gain OCI de 6,7 millions depuis le début de l'année.

Tendances opérationnelles : Les revenus hors intérêts ont diminué de 4 % à 2,6 millions, tandis que les charges hors intérêts ont augmenté de 8 % à 16,7 millions en raison de coûts plus élevés en matière de rémunérations et d'acquisitions. Le ratio d'efficacité s'est légèrement amélioré car la croissance des revenus a dépassé les dépenses. Depuis le début de l'année, une provision négative de 3,5 millions a porté le bénéfice net à 10,8 millions (+23 %).

Capital et dividendes : 9,84 millions d'actions en circulation ; dividende en espèces augmenté à 0,11 $ par action (contre 0,10 $). La société a racheté 71 000 actions depuis le début de l'année et a reçu 17,3 millions de dollars de produits d'une émission en attente d'actions préférentielles de série A.

Les principaux indicateurs de risque restent stables ; aucune dégradation significative du crédit n’a été signalée. La direction continue de se concentrer sur l’élargissement des marges, la réorganisation du bilan vers des dépôts non rémunérés et le retour de capital.

Investar Holding Corp. (ISTR) Q2 2025 10-Q Highlights

Der Nettogewinn stieg im Jahresvergleich um 11 % auf 4,5 Millionen US-Dollar, wodurch das Basis-Gewinn pro Aktie (EPS) von 0,41 $ auf 0,46 $ anstieg. Höhere ٳٴdzԲٰä (+14 % YoY auf 19,6 Millionen US-Dollar) übertrafen eine moderate Kreditverlustrückstellung von 0,1 Millionen US-Dollar (im Vergleich zu einer Auflösung von 0,4 Millionen im Vorjahr). Die gesamten Zinsaufwendungen sanken um 15 % auf 15,7 Millionen US-Dollar, was niedrigeren Kreditkosten entspricht, während die Zinserträge mit 35,4 Millionen stabil blieben.

Bilanz: Die Aktiva wuchsen auf 2,75 Milliarden US-Dollar (+1 % gegenüber Dezember 2024). Die Kredite sanken um 0,9 % auf 2,11 Milliarden, während die Einlagen mit 2,34 Milliarden im Wesentlichen stabil blieben (nicht verzinsliche Einlagen +3,8 %; verzinsliche Einlagen -1,3 %). Die Rückstellung für Kreditverluste blieb stabil bei 26,6 Millionen US-Dollar (1,26 % der Kredite). Das materielle Eigenkapital verbesserte sich auf 255,9 Millionen, da die unrealisierte AFS-Verluste von -48,4 Millionen auf -41,6 Millionen zurückgingen, unterstützt durch einen OCI-Gewinn von 6,7 Millionen im laufenden Jahr.

Operative Trends: Die Erträge ohne Zinsen sanken um 4 % auf 2,6 Millionen, während die Aufwendungen ohne Zinsen aufgrund höherer Vergütungs- und Akquisitionskosten um 8 % auf 16,7 Millionen stiegen. Die Effizienzquote verbesserte sich leicht, da das Umsatzwachstum die Kosten überstieg. Im Jahresverlauf führte eine negative Rückstellung von 3,5 Millionen zu einem Nettogewinn von 10,8 Millionen (+23 %).

Kapital & Dividenden: 9,84 Millionen ausstehende Aktien; Bardividende wurde auf 0,11 $ pro Aktie erhöht (vorher 0,10 $). Das Unternehmen hat im laufenden Jahr 71.000 Aktien zurückgekauft und 17,3 Millionen US-Dollar aus einem ausstehenden Series-A-Vorzugsaktien-Angebot erhalten.

Wesentliche Risikokennzahlen bleiben stabil; keine wesentliche Kreditverschlechterung gemeldet. Das Management konzentriert sich weiterhin auf die Ausweitung der Spreads, die Bilanzumstrukturierung zugunsten nicht verzinslicher Einlagen und die Kapitalrückführung.






As filed with the Securities and Exchange Commission on August 6, 2025
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
76-0474169
(I.R.S. Employer
Identification No.)
2445 Technology Forest Blvd., 11th Floor
The Woodlands, Texas
(Address of Principal Executive Offices)

77381
(Zip Code)
____________________
2017 Equity Incentive Plan
2017 Non-Employee Directors' Equity Incentive Plan
(Full titles of the plan)
____________________
Michael S. Exton, Ph.D.
Chief Executive Officer
2445 Technology Forest Blvd., 11th Floor
The Woodlands, Texas 77381
(281) 863-3000
(Name, address and telephone number, including area code, of agent for service)
____________________
copies to:
Jackson A. O'Maley
Vinson & Elkins L.L.P.
1001 Fannin, Suite 2500
Houston, Texas 77002-6760
(713) 758-2222
Brian T. Crum
Senior Vice President and General Counsel
Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Blvd., 11th Floor
The Woodlands, Texas 77381
(281) 863-3000
____________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  Large accelerated filer o   Accelerated filer o Non-accelerated filer  þ   Smaller reporting company þ Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o





EXPLANATORY NOTE

Lexicon Pharmaceuticals, Inc. (the “Company”) previously filed registration statements on Form S-8 (Registration Nos. 333-41532, 333-168678, 333-183020, 333-210145, 333-217873, 333-234569, 333-240169, 333-258568 and 333-273683) registering the issuance of an aggregate of 55,000,000 shares of the Company's common stock under its 2017 Equity Incentive Plan and an aggregate of 2,000,000 shares of the Company’s common stock under its 2017 Non-Employee Directors' Equity Incentive Plan.
On June 2, 2025, the Company’s stockholders approved an amendment of the 2017 Equity Incentive Plan that increased the total number of shares of the Company’s common stock that may be issued pursuant to stock awards granted under the plan from 55,000,000 to 75,000,000 shares.

On June 2, 2025, the Company’s stockholders approved an amendment of the 2017 Non-Employee Directors’ Equity Incentive Plan that increased the total number of shares of the Company’s common stock that may be issued pursuant to stock awards granted under the plan from 2,000,000 to 4,000,000 shares.

Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, this registration statement on Form S-8 is being filed by the Company for the purpose of registering the issuance of an additional 22,000,000 shares of the Company's common stock under the 2017 Equity Incentive Plan and an additional 2,200,000 shares of the Company’s common stock under the 2017 Non-Employee Directors’ Equity Incentive Plan as a result of such increases in the number of shares reserved for issuance under the plans. This registration statement will increase the number of shares registered under the 2017 Equity Incentive Plan and 2017 Non-Employee Directors’ Equity Incentive Plan to 77,000,000 and 4,200,000 shares, respectively. The content contained in the Company’s registration statements on Form S-8 (Registration Nos. 333-41532, 333-168678, 333-183020, 333-210145, 333-217873, 333-234569, 333-240169, 333-258568 and 333-273683) is hereby incorporated by reference pursuant to General Instruction E.


II-2


PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8.    Exhibits.
Exhibit No.Description
3.1
Sixth Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K dated May 10, 2024 and incorporated by reference herein).
3.2
Second Amended and Restated Bylaws (filed as Exhibit 3.2 to the Company’s Current Report on Form 8-K dated April 26, 2012 and incorporated by reference herein).
4.1
Securities Purchase Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).
4.2
Amendment, dated October 7, 2009, to Securities Purchase Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated October 7, 2009 and incorporated by reference herein).
4.3
Registration Rights Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).
4.4
Stockholders’ Agreement, dated June 17, 2007, with Invus, L.P. (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K dated June 17, 2007 and incorporated by reference herein).
4.5
Supplement to Transaction Agreements, dated March 15, 2010, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated March 15, 2010 and incorporated by reference herein).
4.6
Supplement No. 2 to Transaction Agreements, dated February 23, 2012, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated February 23, 2012 and incorporated by reference herein).
4.7
Supplement No. 3 to the Transaction Agreements, dated December 16, 2020, with Invus, L.P. and Invus C.V. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated December 16, 2020 and incorporated by reference herein).
4.8
Description of Common Stock (filed as Exhibit 4.8 to the Company's Annual Report on Form 10-K for the period ended December 31, 2021 and incorporated by reference herein).
*5.1
Opinion of Vinson & Elkins L.L.P.
*23.1
Consent of Independent Registered Public Accounting Firm.
*23.2Consent of Vinson & Elkins L.L.P. (contained in Exhibit 5.1).
*24.1Power of Attorney (contained in signature page).
99.1
2017 Equity Incentive Plan, as amended (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated June 2, 2025 and incorporated by reference herein).
99.2
2017 Non-Employee Directors' Equity Incentive Plan, as amended (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K dated June 2, 2025 and incorporated by reference herein).
*107.1
Calculation of Filing Fee Tables.
                    
    *    Filed herewith.

II-3


SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of The Woodlands, in the State of Texas, on August 6, 2025.
Lexicon Pharmaceuticals, Inc.
By:/s/ Michael S. Exton, Ph.D.
Michael S. Exton, Ph.D.
Chief Executive Officer


POWER OF ATTORNEY
Each person whose signature appears below appoints Michael S. Exton, Ph.D. and Scott M. Coiante, and each of them, any of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or would do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute and substitutes, may lawfully do or cause to be done by virtue hereof.
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED, THIS REGISTRATION STATEMENT HAS BEEN SIGNED BY THE FOLLOWING PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED BELOW.
SignatureTitleDate
/s/ Michael S. Exton, Ph.D.Chief Executive Officer and Director
(Principal Executive Officer)
August 6, 2025
Michael S. Exton, Ph.D.
/s/ Scott M. CoianteSenior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)August 6, 2025
Scott M. Coiante
/s/ Raymond DebbaneChairman of the Board of DirectorsAugust 6, 2025
Raymond Debbane
/s/ Philippe J. AmouyalDirectorAugust 6, 2025
Philippe J. Amouyal
II-4


/s/ Samuel L. BarkerDirectorAugust 6, 2025
Samuel L. Barker, Ph.D.
/s/ Ivan H. CheungDirectorAugust 6, 2025
Ivan H. Cheung
/s/ Christopher J. SobeckiDirectorAugust 6, 2025
Christopher J. Sobecki
/s/ Diane E. SullivanDirectorAugust 6, 2025
Diane E. Sullivan
/s/ Judith L. SwainDirectorAugust 6, 2025
Judith L. Swain, M.D.

II-5

FAQ

What was ISTR’s Q2 2025 earnings per share?

Basic EPS was $0.46, up from $0.41 in Q2 2024.

How did Investar’s net interest income change year over year?

Net interest income increased 14% to $19.6 million in Q2 2025.

What is the size of Investar’s loan portfolio as of June 30 2025?

Total loans were $2.11 billion, down from $2.13 billion at year-end.

How much unrealized loss is embedded in the AFS securities portfolio?

Unrealized losses total $53.4 million, improved from $61.7 million at December 31 2024.

Did Investar increase its dividend?

Yes. The quarterly dividend was raised to $0.11 per share (from $0.10).

What proceeds did the company receive from preferred stock in the period?

ISTR recorded $17.3 million in advanced proceeds from a Series A preferred offering.
Lexicon Pharmaceuticals Inc

NASDAQ:LXRX

LXRX Rankings

LXRX Latest News

LXRX Latest SEC Filings

LXRX Stock Data

381.34M
358.72M
1.17%
76.53%
8.04%
Biotechnology
Pharmaceutical Preparations
United States
THE WOODLANDS